Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ID110521156
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yunovia Gets MFDS Approval for Phase 1 MAD Study of GLP-1 Agonist
Details : ID110521156 is an orally available small molecule agonist of the GLP-1 receptor. It is being developed for the treatment of obesity and diabetes
Brand Name : ID110521156
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 27, 2024
Lead Product(s) : ID110521156
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?